Cystic fibrosis (CF) is the most common autosomal recessive disease in the Caucasian
population. Cystic fibrosis-related liver disease (CFLD) is defined as the pathogenesis …

Highly effective CFTR modulator drug therapy is increasingly available to those with cystic
fibrosis. Multiple observational research studies are now being conducted to better …

Objective Cystic fibrosis associated liver disease (CFLD) is the third largest cause of
mortality in CF. Our aim was to define the burden of CFLD in the UK using national registry …

Cystic fibrosis (CF) may cause a spectrum of hepatobiliary complications, including portal
hypertension, multilobular cirrhosis, and liver failure. Current guidelines on the detection …

Cystic fibrosis liver disease (CFLD) is characterised by a wide heterogenity of manifestations
and severity. It represents a major cause of morbidity in people with cystic fibrosis (PwCF) …

Rationale: Limited data exist on the safety and effectiveness of elexacaftor-tezacaftor-
ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease. Objectives …

Cystic fibrosis (CF) is a monogenic disease caused by mutation of Cftr. CF-associated liver
disease (CFLD) is a common nonpulmonary cause of mortality in CF and accounts for …

Although cystic fibrosis (CF) is recognized as a monogenic disease, due to variants within
the CFTR (Cystic Fibrosis Transmembrane Regulator) gene, an extreme clinical …

Chronic liver disease incidence is increasing among children worldwide due to a multitude
of epidemiological changes. Most of these chronic insults to the pediatric liver progress to …

Abstract In 2015, the Chinese Society of Hepatology and the Chinese Society of
Gastroenterology issued a consensus statement on the diagnosis and management of …